News
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback